New Technology
The left atrial appendage (LAA) was regarded as the devil of thromboembolic stroke in the patients with nonvalvular atrial fibrillation. [1, 2] The transcatheter LAA closure has significantly advanced in the past two decades and been proved noninferiorly or even superiorly to warfarin in terms of stroke prevention. [3] [4] [5] [6] However, as the limitations of occluders' designs and operational procedures, it is not currently available for all LAA, i.e., the LAA with a definite thrombus. Whether the presence of dense spontaneous echocardiographic contrast (SEC) should be regarded equivalently as a thrombus is still controversial. [7] The patients with dense SEC within the LAA have a higher stroke risk of 18.2%/year if they are not treated with warfarin, or have a 4.5%/year stroke rate with adjusted-dose warfarin. [8] Up to now, the percutaneous closure of the LAA with dense SEC should also be cautious for the current widely used LAA closure systems.
LAmbre is a newly-designed LAA closure system, [9, 10] which is now evaluated by the phase 3 clinical trial both in Europe and China. The LAmbre implantor has two main composes, the fixed umbrella used to fix in the internal wall of LAA and the sealing disc to cover the orifice of LAA [ Figure 1a ].
Unlike the operational protocol of WATCHMAN device, the LAmbre could be unsheathed outside of the LAA [ Figure 1b] , then advanced to depress the umbrella slowly [ Figure 1c ] and fixed in the landing zone [ Figure 1d ]. Subsequently, the unsheathment of the sealing disc [ Figure 1e ] and depressure completely [ Figure 1f ] was conducted to cover the LAA ostium.
case presentation
A 49-year-old Chinese male with persistent atrial fibrillation was referred to our center for percutaneous LAA closure. The patient had a history of hypertension, type-2 diabetes mellitus, and one event of a previous ischemic stroke. After route laboratory tests on admission, there were not any contraindications for LAA closure. The route radiofrequency ablation was refused; thus, the LAA closure should be conducted directly. Before the procedure of LAA closure, both the long-axis and the short-axis views of TEE images were measured to illustrate the maximal LAA orifice diameter of 20 mm [ Figure 3a , full line] and landing zone of 22 mm [ Figure 3a, dotted lines] . Thus, a size of 26 mm (diameter of the fixed umbrella) plus 32 mm (diameter of sealing disc) was designated, according to the manufacturer's advice. [10] The LAA closure was conducted with the guidance of TEE in general anesthesia. Following transseptal puncture inferoposteriorly, a very small quantity of contrast was injected through the outer sheath to show just the direction of LAA [ Figure 3b ]. Then, the outer sheath was adjusted to be coaxial with the long diameter of LAA, and the delivery sheath containing the compressed occluder was advanced slowly to release the fixed umbrella [ Figure 3c ] and fixed in the landing zone [ Figure 3d ]. After a slight pulling to make sure the good fixation of fixed umbrella, the delivery sheath was kept still while the outer sheath was dropped out to depress the sealing disc [ Figure 3e ] to cover the orifice of LAA. Before and after the releasement with counterclockwise rotation of the core wire, cineangiographies showed there were no obvious residual Figure 3f and g]. Monitoring TEE also showed well closure of LAA and no extension to the left upper pulmonary vein and mitral valve.
The total time cost of the operation was 45 min and the time of in-to-out sheath was just 15 min. The total cost of contrast used was about 30 ml. The patient underwent a uneventful recovery and discharged 3 days after the operation. He would receive dual-antiplatelet therapies with aspirin 100 mg/day and clopidogrel 75 mg/day for 6 months. There was no severe adverse event after 3-month follow-ups.
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